ADVERTISEMENT
Manila Bulletin devider Philippines devider National devider VCO, lagundi, tawa-tawa clinical trials eyed to be completed by June - DOST

VCO, lagundi, tawa-tawa clinical trials eyed to be completed by June - DOST

Published May 3, 2021 06:25 pm

Clinical trials on the use of the Virgin Coconut Oil (VCO), lagundi (Chinese chaste tree), and tawa-tawa (Euphorbia hirta) as a coronavirus disease (COVID-19) therapeutic or supplement are expected to be completed by June, the Department of Science and Technology-Philippine Council for Health Research and Development (DOST-PCHRD) said on Monday, May 3.

(Manila Bulletin File Photos)

DOST-PCHRD Executive Director Dr. Jaime C. Montoya expressed optimism that studies on the herbal medicines as a potential supplement that could help prevent the worsening of condition in patients afflicted with the COVID-19 virus will be concluded next month.

“Itong lagundi, tawa-tawa at VCO, sana ay matapos na at ang target po natin ay katapusan ng Hunyo, pero po maraming pag-aaral na nagsisimula rin na bago na iba ibang indikasyon ang tinintingan so maaari na magoverlap (These clinical trials on lagundi, tawa-tawa and VCO, hopefully, they will be completed soon, and our target is by end of June, but there are many studies that are also starting and other indications are being looked at so it can overlap),” he said during a televised public briefing on Monday.

“Pero sa pangkalahatan nakikita po namin basta wala pong problema at ma-achieve yung target na sample size po sa mga pag-aaral, sana po ay matapos around June (But in general, we see that as long as there are no problems and we can achieve the target sample size in the studies, we hope to finish around June),” he added.

In April last year, the DOST started looking into the effectiveness of certain herbal medicines against COVID-19.

During his weekly report on Friday, April 9, DOST Secretary Fortunato “Boy” T. de la Peña announced that the screening and recruitment for participants of VCO clinical trials are still ongoing. VCO clinical trials are being conducted at the Philippine General Hospital (PGH) and in Valenzuela City.

https://mb.com.ph/2021/04/10/vco-clinical-trials-still-ongoing-dost/

De la Peña said they were bracing for the immediate completion of the Stage 2 of the lagundi clinical trials with the inclusion of more trial centers, such as quarantine centers in Quezon City.

https://mb.com.ph/2021/04/12/dost-braces-for-immediate-completion-of-stage-2-lagundi-clinical-trials/

The DOST chief said over 150 COVID-19 patients were enrolled to participate in the Stage 2 of the lagundi clinical trials.

http://https://mb.com.ph/2021/04/10/159-covid-19-patients-to-participate-in-phase-2-of-lagundi-clinical-trials/

In late March, Dr. Cecilia Nelia C. Maramba-Lazarte of the University of the Philippines (UP) Manila announced that the lagundi clinical trials are expected to be completed soon.

She said they completed the Stage 1 of the trials or the dose-finding and safety study at the Quezon Institute and at the PNP Camp Bagong Final Special Care Facility.

https://mb.com.ph/2021/03/26/clinical-trials-for-lagundi-as-covid-19-therapeutic-near-completion/

In July 2020, it was announced that the clinical trials for lagundi were approved by DOST-Philippine Council for Health Research and Development (PCHRD).

Lagundi is widely used as a cough remedy.

In early April this year, de la Peña announced that Quezon Institute will serve as a “new study site” for clinical trial on the use of tawa-tawa as an adjunctive treatment of mild to moderate COVID-19 patients.

In late March, Dr. Philip Ian Padilla of the University of the Philippines (UP) Visayas relayed to de la Peña that the taw-tawa clinical trial is just starting.

He said the clinical trial for tawa-tawa has been slightly delayed “because of bureaucratic red tape.”

https://mb.com.ph/2021/03/27/clinical-trial-for-tawa-tawa-as-adjunctive-covid-treatment-starts/

Tawa-tawa is known as a supplement for dengue.

Related Tags

vco Coconut june CLINICALTRIALS LAGUNDI TAWATAWA DOST
ADVERTISEMENT
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1561_widget.title }}

{{ item.title }}
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1562_widget.title }}

{{ item.title }}
.most-popular .layout-ratio{ padding-bottom: 79.13%; } @media (min-width: 768px) and (max-width: 1024px) { .widget-title { font-size: 15px !important; } }

{{ articles_filter_1563_widget.title }}

{{ item.title }}

{{ articles_filter_1564_widget.title }}

{{ item.title }}
.mb-article-details { position: relative; } .mb-article-details .article-body-preview, .mb-article-details .article-body-summary{ font-size: 17px; line-height: 30px; font-family: "Libre Caslon Text", serif; color: #000; } .mb-article-details .article-body-preview iframe , .mb-article-details .article-body-summary iframe{ width: 100%; margin: auto; } .read-more-background { background: linear-gradient(180deg, color(display-p3 1.000 1.000 1.000 / 0) 13.75%, color(display-p3 1.000 1.000 1.000 / 0.8) 30.79%, color(display-p3 1.000 1.000 1.000) 72.5%); position: absolute; height: 200px; width: 100%; bottom: 0; display: flex; justify-content: center; align-items: center; padding: 0; } .read-more-background a{ color: #000; } .read-more-btn { padding: 17px 45px; font-family: Inter; font-weight: 700; font-size: 18px; line-height: 16px; text-align: center; vertical-align: middle; border: 1px solid black; background-color: white; } .hidden { display: none; }
function initializeAllSwipers() { // Get all hidden inputs with cms_article_id document.querySelectorAll('[id^="cms_article_id_"]').forEach(function (input) { const cmsArticleId = input.value; const articleSelector = '#article-' + cmsArticleId + ' .body_images'; const swiperElement = document.querySelector(articleSelector); if (swiperElement && !swiperElement.classList.contains('swiper-initialized')) { new Swiper(articleSelector, { loop: true, pagination: false, navigation: { nextEl: '#article-' + cmsArticleId + ' .swiper-button-next', prevEl: '#article-' + cmsArticleId + ' .swiper-button-prev', }, }); } }); } setTimeout(initializeAllSwipers, 3000); const intersectionObserver = new IntersectionObserver( (entries) => { entries.forEach((entry) => { if (entry.isIntersecting) { const newUrl = entry.target.getAttribute("data-url"); if (newUrl) { history.pushState(null, null, newUrl); let article = entry.target; // Extract metadata const author = article.querySelector('.author-section').textContent.replace('By', '').trim(); const section = article.querySelector('.section-info ').textContent.replace(' ', ' '); const title = article.querySelector('.article-title h1').textContent; // Parse URL for Chartbeat path format const parsedUrl = new URL(newUrl, window.location.origin); const cleanUrl = parsedUrl.host + parsedUrl.pathname; // Update Chartbeat configuration if (typeof window._sf_async_config !== 'undefined') { window._sf_async_config.path = cleanUrl; window._sf_async_config.sections = section; window._sf_async_config.authors = author; } // Track virtual page view with Chartbeat if (typeof pSUPERFLY !== 'undefined' && typeof pSUPERFLY.virtualPage === 'function') { try { pSUPERFLY.virtualPage({ path: cleanUrl, title: title, sections: section, authors: author }); } catch (error) { console.error('ping error', error); } } // Optional: Update document title if (title && title !== document.title) { document.title = title; } } } }); }, { threshold: 0.1 } ); function showArticleBody(button) { const article = button.closest("article"); const summary = article.querySelector(".article-body-summary"); const body = article.querySelector(".article-body-preview"); const readMoreSection = article.querySelector(".read-more-background"); // Hide summary and read-more section summary.style.display = "none"; readMoreSection.style.display = "none"; // Show the full article body body.classList.remove("hidden"); } document.addEventListener("DOMContentLoaded", () => { let loadCount = 0; // Track how many times articles are loaded const offset = [1, 2, 3, 4, 5, 6, 7, 8, 9, 10]; // Offset values const currentUrl = window.location.pathname.substring(1); let isLoading = false; // Prevent multiple calls if (!currentUrl) { console.log("Current URL is invalid."); return; } const sentinel = document.getElementById("load-more-sentinel"); if (!sentinel) { console.log("Sentinel element not found."); return; } function isSentinelVisible() { const rect = sentinel.getBoundingClientRect(); return ( rect.top < window.innerHeight && rect.bottom >= 0 ); } function onScroll() { if (isLoading) return; if (isSentinelVisible()) { if (loadCount >= offset.length) { console.log("Maximum load attempts reached."); window.removeEventListener("scroll", onScroll); return; } isLoading = true; const currentOffset = offset[loadCount]; window.loadMoreItems().then(() => { let article = document.querySelector('#widget_1690 > div:nth-last-of-type(2) article'); intersectionObserver.observe(article) loadCount++; }).catch(error => { console.error("Error loading more items:", error); }).finally(() => { isLoading = false; }); } } window.addEventListener("scroll", onScroll); });
Join Our Newsletters

Sign up by email to receive news.

© 2025 Manila Bulletin The Nation's Leading Newspaper. All Rights Reserved.